Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma

書誌詳細
主要な著者:	Shrimanker, R, Pavord, I, Price, R, Bradford, E, Keene, O, Yancey, S
フォーマット:	Conference item
出版事項:	American Thoracic Society 2018

類似資料

Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
著者:: Shrimanker, R, 等
出版事項: (2019)

Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
著者:: Gunsoy, N, 等
出版事項: (2017)

Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
著者:: Steven W. Yancey, 等
出版事項: (2019-09-01)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
著者:: Howell, I, 等
出版事項: (2024)

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
著者:: Bel, E, 等
出版事項: (2014)

Mepolizumab treatment in patients with severe eosinophilic asthma.
著者:: Ortega, H, 等
出版事項: (2014)

Glucocorticoids and mepolizumab in eosinophilic asthma.
著者:: Bel, E, 等
出版事項: (2014)

Mepolizumab in refractory eosinophilic asthma.
著者:: Pavord, I, 等
出版事項: (2010)

Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
著者:: Imran Howell, 等
出版事項: (2024-07-01)

Mepolizumab for eosinophilic COPD
著者:: Sciurba, F, 等
出版事項: (2018)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
著者:: Price, D, 等
出版事項: (2019)

Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma
著者:: Yancey, S, 等
出版事項: (2016)

Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma
著者:: Jiang-Hua Li, 等
出版事項: (2021-08-01)

Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations
著者:: David B. Price, 等
出版事項: (2019-08-01)

Mepolizumab, quality of life, and severe eosinophilic asthma.
著者:: Pavord, I
出版事項: (2017)

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
著者:: Ortega, H, 等
出版事項: (2016)

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma
著者:: Shrimanker, R, 等
出版事項: (2017)

Mepolizumab and exacerbations of refractory eosinophilic asthma.
著者:: Haldar, P, 等
出版事項: (2009)

Biomarkers for severe eosinophilic asthma.
著者:: Yancey, S, 等
出版事項: (2017)

Blood eosinophil depletion with mepolizumab, benralizumab and prednisolone in eosinophilic asthma
著者:: Moran, AM, 等
出版事項: (2020)

Evaluation of sputum eosinophil count as a predictor of treatment response to mepolizumab
著者:: Ian D. Pavord, 等
出版事項: (2022-05-01)

Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo
著者:: Shrimanker, R, 等
出版事項: (2017)

Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts
著者:: Arian Ghassemian, 等
出版事項: (2021-01-01)

The peripheral blood eosinophil count as a biomarker of eosinophilic airway inflammation in patients with asthma and COPD. Experience from a single centre
著者:: Shrimanker, R, 等
出版事項: (2017)

Mepolizumab for eosinophilic chronic obstructive pulmonary disease
著者:: Pavord, I, 等
出版事項: (2017)

Association between fractional exhaled nitric oxide, sputum induction and peripheral blood eosinophil in uncontrolled asthma
著者:: Jie Gao, 等
出版事項: (2018-05-01)

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma
著者:: Terufumi Shimoda, 等
出版事項: (2017-07-01)

Does a composite score combining peripheral blood eosinophils (PBE) and exhaled nitric oxide (FeNO) accurately predict a sputum eosinophilia?
著者:: Connolly, CM, 等
出版事項: (2017)

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
著者:: Pavord, I, 等
出版事項: (2012)

Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes
著者:: Prazma CM, 等
出版事項: (2021-06-01)

Both fractional exhaled nitric oxide and sputum eosinophil were associated with uncontrolled asthma
著者:: Gao J, 等
出版事項: (2018-04-01)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
著者:: Menzella F, 等
出版事項: (2016-06-01)

Late breaking abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
著者:: Pavord, I, 等
出版事項: (2017)

Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis
著者:: Charlene M. Prazma, 等
出版事項: (2019-05-01)

Blood eosinophil phenotype during treatment with mepolizumab in patients with severe eosinophilic asthma
著者:: Chio Sakai, 等
出版事項: (2024-07-01)

The use of exhaled nitric oxide concentration to identify eosinophilic airway inflammation: an observational study in adults with asthma.
著者:: Berry, M, 等
出版事項: (2005)

Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
著者:: Wechsler, M, 等
出版事項: (2017)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
著者:: Buendía, JA, 等
出版事項: (2022)

Fractional exhaled nitric oxide and eosinophil count in induced sputum to guide the management of children with asthma: a cost-utility analysis
著者:: Jefferson Antonio Buendía, 等
出版事項: (2022-06-01)

Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts
著者:: Yuki Hoshino, 等
出版事項: (2022-04-01)